Stella Pharma (TSE:4888) Marketable Securities: 円0.0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4888 Stella Pharma Corp TSE:4888
76 GF Score
Price 円328.00
GF Value 円369.52
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Stella Pharma Marketable Securities?

Stella Pharma TSE:4888 +0.92% 76 Marketable Securities is 円0.0 Mil as of Mar. 2026. GuruFocus rates TSE:4888 with a GF Score™ of 76/100 and a GF Value™ of 円369.52 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Stella Pharma's Marketable Securities for the quarter that ended in Mar. 2026 was 円0.0 Mil.

Stella Pharma's annual Marketable Securities declined from Mar. 2024 (円300.9 Mil) to Mar. 2025 (円0.0 Mil) but then stayed the same from Mar. 2025 (円0.0 Mil) to Mar. 2026 (円0.0 Mil).

Stella Pharma  (TSE:4888) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Stella Pharma Marketable Securities Related Terms

Stella Pharma Marketable Securities Historical Data

* Premium members only.

The historical data trend for Stella Pharma's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Stella Pharma Marketable Securities Chart

Stella Pharma Annual Data
Trend Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Marketable Securities
Get a 7-Day Free Trial 0.00 0.00 300.94 0.00 0.00

Stella Pharma Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
TSE:4888
76GF Score
Stella Pharma Corp TSE:4888
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Stella Pharma Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of 円0.0 Mil mean?
Stella Pharma (TSE:4888) has a Marketable Securities of 円0.0 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Stella Pharma and its competitors.
Is Stella Pharma's Marketable Securities too high?
Stella Pharma's current Marketable Securities is 円0.0 Mil. Overall, Stella Pharma has a GF Score™ of 76/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Stella Pharma's Marketable Securities compare to VRTX and REGN?
Stella Pharma's Marketable Securities of 円0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Stella Pharma and its competitors. Stella Pharma's current Marketable Securities is 円0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stella Pharma stock overvalued right now?
Based on GuruFocus' analysis, Stella Pharma (TSE:4888) is currently considered Modestly Undervalued. The stock's GF Value™ is 円369.52, compared to a current price of 円328.00 — trading 11.2% below its estimated fair value. The current Marketable Securities is 円0.0 Mil. Stella Pharma's overall GF Score™ is 76/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Stella Pharma (TSE:4888), the current Marketable Securities is 円0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Stella Pharma (TSE:4888) Overvalued in 2026?

Based on GuruFocus' analysis, Stella Pharma stock appears to be undervalued. The current stock price of 円328.00 is trading 11.2% below its estimated GF Value™ of 円369.52. GuruFocus considers Stella Pharma to be Modestly Undervalued.

Key valuation signals for TSE:4888:

  • Marketable Securities: 円0.0 Mil
  • GF Value™: 円369.52 vs. price of 円328.00 (11.2% below fair value)
  • GF Score™: 76/100 with 4 warning signs

No single metric tells the full story. See the TSE:4888 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Stella Pharma Business Description

Address 3-2-7 Korai-bashi, Chuo-ku, Osaka Prefecture, Osaka, JPN, 541-0043
Stella Pharma Corp is a therapeutic drug research and development company. It is focused on the development of boron compounds, particularly used in boron neutron capture therapy (BNCT). The BNCT is a form of cancer radiation therapy for destroying cancer cells.
76GF Score

Get the complete analysis for TSE:4888

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円328.00
Price
円369.52
GF Value